Helixgate https://validator.w3.org/feed/docs/rss2.html AbbVie faces questions about Skyrizi competition from J&J AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate “Click Clotting” Technique Rapidly Creates Stronger Blood Clots STAT+: Why conversations around health AI may be evolving beyond hype Supply Chain Digital Twins: An Evolution, Not a Breakthrough Teva nabs experimental Tourette drug in $700M Emalex buyout Loss of Smell Therapies Informed by Olfactory Receptor Spatial Mapping Chiesi to buy KalVista in $1.9B deal for rare disease drug Bristol Myers reaches a crossroads as a make-or-break year takes shape With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’ Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings Meet the Researcher: Fred Ramsdell, Nobel winner  Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly A patent win for Pfizer and BridgeBio Chiesi signs $1.9B deal to acquire KalVista and its approved drug AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins GSK’s Shingrix strategy shift drives sales beat even as vaccines slow Pfizer settles with generic drugmakers to protect blockbuster drug until 2031 Food safety experts warn of USDA brain drain AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions Hepatocyte Detargeting Improves mRNA Vaccine Immunity in Lymphoma Model Opinion: The medical school nutrition blues Opinion: STAT+: Did Kennedy just stack the deck on FDA oversight of peptides? Biotech angels lean into deeper diligence and disciplined early bets Altitude Labs serves up higher education for biotech founders Lilly can’t stop the dealing, with nearly $21B spent on M&A this year—so far Patient advocate offers Recursion a powerful reason to keep going in rare disease New report shows some health equity wins. Experts fear they will be short-lived In first meeting, federal autism committee focuses on ‘profound autism’ Tuning the immune response to mRNA vaccines STAT+: Health system CEOs get off easy at Congressional hearing on affordability  STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead STAT+: FDA launches effort to speed up clinical trials, using AI Method Identifies Cellular Makeup of Microenvironments Favoring Tumor Metastasis Opinion: Healthcare or health care? Help STAT decide FDA debuts plan to collect real-time clinical trial data The crown for healthcare admin tech is still up for grabs Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug development Hikma vs. Amarin generic drug case heads to Supreme Court arguments Fauci adviser David Morens indicted for concealing emails, avoiding records requests ‘Type’ Casting: Flagship-Founded Serif Modifying DNA into New Therapy Class Pfizer deals extend patent life for a top-selling rare disease drug Boehringer dual-acting obesity shot hits mark in Phase 3 trial Prostate Cancer Therapy Targets Disordered Region of Androgen Receptor Home